MDGH and TDR, the Special Programme for Research and Training in Tropical Diseases, are proud to announce that moxidectin has been nominated for ‘Best Pharmaceutical Product’ in the prestigious Prix Galien USA Awards for 2019.
Awarded annually, the Prix Galien Award recognises outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The award was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
Moxidectin is in the company of 21 innovative nominees this year, but moxidectin is the only one approved for the treatment of a Neglected Tropical Disease (NTD). Read the full list of nominees here.
Mark Sullivan, Founder and Managing Director of MDGH, said: “This nomination is a tribute to the vision and tenacity of TDR, who were the driving force over a 20-year span, the thousands of scientists in various organisations who worked on moxidectin, the NTD community who called for its development, and those who provided the funding for the work. Moxidectin made it through against the odds.”
The Prix Galien USA Award ceremony will be held in New York City on October 24, 2019.